PCOS name change to PMOS to lead to a holistic approach, involve more disciplines: Prof. Terhi Piltonen

Earlier this year, Polycystic Ovary Syndrome (PCOS) which affects one in eight women worldwide, was renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) by the Endocrine Society.

A global consensus article published in the Lancet in May, led by Professor Helena J. Teede, argued that the name reduced a long-term hormonal and endocrine disorder to focus on ovaries and cysts, leading to inadequate treatment, or fewer people getting diagnosed with the condition.

Professor Terhi Piltonen, president of International Androgen Excess and Polycystic Ovary Syndrome Society (AE-PCOS Society), and also one of the co-leads of the Lancet publication, from Oulu University Hospital, Finland, in conversation with The Hindu speaks about the name change, and its implications on patients, treatment plans, and research.

Can you tell me about the process of renaming the syndrome from PCOS to PMOS?